Allergychoices Company Profile

Background

Founded in 2000, Allergychoices is a healthcare services company specializing in sublingual immunotherapy (SLIT) to treat the root causes of allergic diseases. The company's mission is to provide patients and healthcare providers with access to effective, safe, and affordable allergy treatments. By utilizing the La Crosse Method™ Practice Protocol, developed by founder Dr. David L. Morris, Allergychoices has become a leader in offering personalized allergy care. The company has educated over 2,000 providers and treated more than 275,000 patients, emphasizing the importance of individualized treatment plans.

Key Strategic Focus

Allergychoices focuses on expanding the adoption of sublingual immunotherapy through the La Crosse Method™ Protocol. This approach allows providers to offer personalized allergy treatments that address the underlying causes of allergic diseases. The company targets a broad range of allergic conditions, including asthma, food allergies, sinusitis, and eczema. By partnering with healthcare providers and employer groups, Allergychoices aims to reduce healthcare costs and improve patient outcomes through innovative allergy care solutions.

Financials and Funding

As of the latest available data, Allergychoices has raised a total of $150,000 in funding over one round. The company generates an estimated annual revenue of $6.8 million and employs approximately 18 staff members.

Pipeline Development

Allergychoices' primary offering is the La Crosse Method™ Protocol for sublingual immunotherapy. This protocol has been validated through the treatment of over 275,000 patients and is supported by published studies. The company continues to refine and expand its services, including pharmacy support, skin testing, and practice support, to enhance the effectiveness and accessibility of allergy treatments.

Technological Platform and Innovation

The cornerstone of Allergychoices' innovation is the La Crosse Method™ Protocol, a proprietary approach to sublingual immunotherapy developed by Dr. David L. Morris. This protocol emphasizes personalized treatment plans based on individual patient histories, exams, and testing to identify specific allergies and sensitivity levels. The protocol's outcomes have been validated by the Validation Institute, an independent team of population health scientists and biostatisticians.

Leadership Team

Jeff Kessler, MBA, FACHE: President and Director. Jeff has been with Allergychoices since 2001, bringing extensive experience in healthcare administration. He earned his MBA from the University of Minnesota’s Carlson School of Management and is a Fellow of the American College of Healthcare Executives.

Anne Hendrickson: Chief Operating Officer and Vice President of Operations & Marketing. Anne leads operations and marketing strategies, leveraging over 25 years of experience in brand development and integrated communications. She played a pivotal role in the launch and growth of Allergychoices.

Jim Killoran: Director. As a co-founder, Jim provides strategic development leadership and serves as an advisor to the Board of Directors. His entrepreneurial spirit has been instrumental in the company's growth.

Michael B. Kachel, RPh: Director of Pharmacy. A licensed pharmacist with over 25 years of compounding experience, Mike oversees pharmacy operations, ensuring the delivery of high-quality services to providers and patients.

Leadership Changes

Dr. Mary S. Morris, a founder of Allergychoices and a primary author of the La Crosse Method™ Protocol, is no longer actively involved with the company. Her contributions have been foundational to the company's mission and success.

Competitor Profile

Market Insights and Dynamics

The allergy treatment market is experiencing growth due to increasing prevalence of allergic conditions and a shift towards personalized medicine. Sublingual immunotherapy is gaining traction as a convenient and effective alternative to traditional allergy shots.

Competitor Analysis

Key competitors in the allergy treatment space include:

Shertech Pharmacy: Specializes in compounding pharmacy services, including allergy treatments.

The American College of Allergy, Asthma, and Immunology: A professional medical organization providing education and resources for allergists.

Food Allergy Research & Education (FARE): Focuses on food allergy research and advocacy.

American Academy of Allergy, Asthma & Immunology: Provides education and research in the field of allergy and immunology.

These organizations contribute to the broader landscape of allergy treatment and research, each with distinct areas of focus.

Strategic Collaborations and Partnerships

Allergychoices collaborates with healthcare providers across the United States to implement the La Crosse Method™ Protocol. The company also partners with employer groups through its Allergy Control Program, aiming to reduce healthcare costs and improve employee productivity by addressing allergy-related health issues.

Operational Insights

Allergychoices differentiates itself through its proprietary La Crosse Method™ Protocol, emphasizing personalized and validated sublingual immunotherapy treatments. The company's comprehensive support services, including pharmacy, skin testing, and practice support, provide a seamless experience for both providers and patients. This integrated approach enhances patient adherence and satisfaction, positioning Allergychoices as a leader in the allergy treatment market.

Strategic Opportunities and Future Directions

Looking ahead, Allergychoices aims to expand its network of trained providers and increase patient access to personalized allergy treatments. The company is focused on enhancing its technological platforms to streamline diagnostics and treatment processes further. By continuing to validate and refine the La Crosse Method™ Protocol, Allergychoices seeks to solidify its position as a pioneer in sublingual immunotherapy and personalized allergy care.